Italy-based NTC Srl and Santen Pharmaceutical announced an extension of their original agreement for Europe granting NTC’s license and distribution rights of levofloxacin+dexamethasone fixed combination eye drops to Santen. The countries covered by the extension agreement include Vietnam, Thailand, Singapore, Malaysia, Phillippines, Indonesia, Myanmar, Hong Kong, Macau, Brunei, Laos, Cambodia, Sri Lanka, Bangladesh, and Pakistan.
The levofloxacin+dexamethasone fixed combination in eye drops aims to carry to the ophthalmology community a novelty in the treatment of post-cataract surgery.
To provide supportive evidence to its product, NTC completed the Leader7 international, multicenter, randomized, blinded-assessor, parallel-group clinical study designed to prove that a 1-week course of antibiotic prophylaxis is comparable to a two-week course, thus reducing the unnecessary exposure of patients to antibiotics.
“We are proud of the intense and productive partnership with Santen,” Riccardo Carbucicchio, Chairman and CEO of NTC, said in a news release. “We believe the evidences supporting levofloxacin+dexamethasone will offer great hints to the ophthalmology community and the benefit of better treated patients undergoing cataract surgery.”